French biotechnology company Carmat SAS said Monday it has implanted a pioneering artificial heart made of a mix of synthetic and natural materials in a second patient suffering from chronic heart failure Carmat shares rose as much as  Friday when rumors of the second transplant were reported in the French press Shares in the company were trading down slightly on Monday Carmat
  